ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0326

Assessment of Depression in Ankylosing Spondylitis Using Center for Epidemiologic Studies Depression Scale

Yvette Farran1, Mark Hwang1, John Reveille2, Lianne Gensler3, Accelerating Medicines Partnership Program RA SLE Network4, Mariko Ishimori4 and Michael Ward5, 1The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, 2The University of Texas Health Science Center, Houston, TX, 3University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), depression, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints. Depression is a common comorbidity in AS patients and can have a significant impact on their quality of life. The Center for Epidemiologic Studies Depression Scale (CES-D) is a widely used self-report questionnaire for measuring depression in various populations. However, the validity of CES-D in AS patients is unclear.

Methods: We investigated the psychometrics of the CES-D in AS by studying Prospective Study of Ankylosing Spondylitis (PSOAS) observational cohort patients with baseline, concomitant PHQ9 and self-reported depression. Construct validity was examined through convergent and known-groups validity. CES-D and PHQ9 was assessed using Pearson’s correlation coefficient. Known groups validity for the CESD was tested using student’s t-test comparing patients with and without self-reported depression. To find the optimal cutoffs, ROC curves were made plotting CES-D against Patient reported depression, PHQ9 against Patient report depression and CES-D against PHQ9≥10. The optimal cutoff point was found using Youden’s index.

Results: 846 of the patients from the PSOAS cohort had completed CES-D at their initial visit. Of those, 325 had completed CES-D, PHQ-9, and self-reported depression. 25% (83/325) had PHQ9 > 10, 34% (112/325) had CES-D > 16 and 17% (56/325) had self-reported depression. Of the patients with self-reported depression, the average CES-D score was 19.8 and the average PHQ9 score was 10.7.The CES-D showed strong correlation with PH9 in AS patients (r > 0.82, p < 0.01) (Figure 1).T-test was significant comparing CES-D scores of AS patients with and without self-reported depression (p< .01) with a mean difference of 7.5 (4.6-10.3 95% CI).The ROC curves are shown in Figure 2. AUC’s of these ranged from: 0.69-0.88. The optimal cut off point for CES-D in these patients based on Youden’s index was 17-18.

Conclusion: In our AS patients, the CES-D scores are valid and have good construct validity. CES-D correlated well with self-reported depression and PHQ9. This suggests that CES-D is valid in this patient population and that a CES-D cutoff of 18, like that found in Rheumatoid Arthritis patients1, may be a better cutoff value to indicate depression in AS patients.

Supporting image 1

Supporting image 2


Disclosures: Y. Farran: None; M. Hwang: None; J. Reveille: None; L. Gensler: AbbVie, 2, Acelyrin, 2, Eli Lilly, 2, Fresenius Kabi, 2, Janssen, 2, Novartis, 2, 5, Pfizer, 2, UCB Pharma, 2, 5; A. RA SLE Network: None; M. Ishimori: None; M. Ward: None.

To cite this abstract in AMA style:

Farran Y, Hwang M, Reveille J, Gensler L, RA SLE Network A, Ishimori M, Ward M. Assessment of Depression in Ankylosing Spondylitis Using Center for Epidemiologic Studies Depression Scale [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/assessment-of-depression-in-ankylosing-spondylitis-using-center-for-epidemiologic-studies-depression-scale/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-depression-in-ankylosing-spondylitis-using-center-for-epidemiologic-studies-depression-scale/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology